 BATAR: INDIVIDUALS CURRENTLY TAKING BOOSTED ATAZANAVIR AS PART OF AN HIV TREATMENT REGIMEN WILL BE EVALUATED TO SEE IF SUBSTITUTING RALTEGRAVIR FOR NUCLEOSIDE TRANSCRIPTASE INHIBITORS WILL BE SAFE AND WELL TOLERATED.: 